The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Resolvedstocks

Medicus Pharma Reports 80% Response Rate in SkinJect Phase 2 Clinical Trials

First Detected: Mar 30, 2026, 11:49 AM

Last Update: 4 months ago

6 articles·4 stories

Event Summary

Medicus Pharma reported an 80% overall response rate (ORR) in Phase 2 data for SkinJect. Dr. Babar Rao, a key opinion leader, validated that the outcomes are clinically meaningful for treating non-melanoma skin cancer. The treatment could potentially allow the majority of lesions to avoid immediate surgery.

Timeline

Independent Expert Validates Medicus Pharma’s Phase 2 Clinical Data

Apr 4, 2026, 2:16 PMImpact: 4

PolyPid Initiates FDA Rolling Submission for D-PLEX₁₀₀

Mar 31, 2026, 12:54 PMImpact: 6

Incyte Reports Positive 54-Week Clinical Data for Povorcitinib Skin Treatment

Mar 30, 2026, 8:19 PMImpact: 6

Medicus Pharma Reports 80% Response Rate in SkinJect Phase 2 Clinical Trials

Mar 30, 2026, 11:49 AMImpact: 7

Medicus Pharma Reports 80% Response Rate in SkinJect Phase 2 Clinical Trials

Event Summary

Timeline

Price Impact